

CURRICULUM VITAE

Name: **Dee Edward Silver, M.D.**

Address/Professional Experience:

Coastal Neurological Medical Group, Inc. 1973-Present
9850 Genesee Avenue #740
La Jolla, CA 92037
Phone: 858-453-3842
Fax: 858-535-9390

Birth Date:

December 8, 1939; Keystone, Iowa

EDUCATION

Post Residency Training:

UCSD 1972-1973
Dr. R. Bickford, EEG and Neurophysiology

Residency:

University of Iowa, Department of Neurology 1968-1971

Internship:

University of Utah, School of Medicine, Medicine Neurology, and Pediatric Neurology 1967-1968

Medical School:

University of Iowa 1963-1967

Medical Degree:

June 1967

Medical License:

Iowa 1968-1975
California (current) 1971-2013

Education:

Iowa State Teacher's College (now University of Northern Iowa) 1957-1963
Graduate and Undergraduate Work in Science and Music

Iowa State Teacher's College (now University of Northern Iowa) 1957-1961
Cedar Falls, Iowa, BA in Music

High School, Belle Plaine, Iowa 1954-1957

Professional Music Experience, Orchestra:

Floyd Warren Radio Rambler 1958-1962
Charlie Trussel 1959-1961
North Coast Jazz Band 1983-1986

Board Certification:

Medical License, University of Iowa 1967
Board Certified in Neurology, certified August 1973
Passed oral in August 1973, Written in January 1973

Qualified Medical Evaluator:

For industrial medical consult. Examination passed June 29, 1994
Certified by state of California and recertified 1996, July 1998

Board Eligible:

By post residency training in Electroencephalography and Neurophysiology (elected not to take test) 1973

Military Assignments:

Department of Neurology, US Naval Hospital, Balboa San Diego, California 1971-Oct. 1973

Head of Department of Encephalography and Neurophysiology, Head of EEG Training School US Naval Hospital, Balboa, San Diego, California 1971-1973

Head of Department of Neurology, US Naval Hospital, Balboa, San Diego, California 07/1972-10/1973

Lieutenant Commander, US Naval Hospital, Balboa, San Diego, California 1971-1973

Professional Advisor:

Electroencephalography/Electromyography and Neurophysiology Grossmont College, San Diego, California 1971-1973

Assistant Clinical Professor UCSD, San Diego, California 1971-1975

Lecturer-Emergency Medicine Symposium I and II:

Post-graduate Institute of Emergency and Primary Care Physicians UCSD, San Diego, California 1974-1998 Quarterly

Quarterly courses lecturer on subjects

- 1) Headache and Head Pain
- 2) Seizures and Status Epilepticus
- 3) Infectious Diseases of the Nervous System

Author of chapters for subjects in book

- 1) Headache and Head Pain, chapter revised August 1998
- 2) Seizures, chapter revised July 1998
- 3) Infectious Diseases of the Nervous System for Emergency Medicine Text (course text)
- 4) Strokes, chapter written 1998, revised August 1998

Scripps Memorial Hospital TMJ conference 1986-1989

Co-chairman, lecturer on Headache, Head Pain, and TMJ 1986, 1987, 1989

Continuing Medical Education Associates, Inc. Lecturer, Chapters on:

- 1) Headache
- 2) Stroke

Professional Societies:

California Medical Association (current) 1973-2012

California Neurological Society 1975-1976

1998-2010

San Diego Neurological Society (current) 1971-2010

American Academy of Neurology (active) 1971-2012

American Medical Association (current) 1971-2012

American EEG Society 1971-1994

San Diego County Medical Society 1973-2010

American Association for Study of Headache 1986-2012

Movement Disorder Society 1990-2012

Pacific Interurban Clinical Club 1998-2002

Other:

Phi Mu Alpha, Life Member
Nu Sigma Nu, Life Member

Completion of Rater Training:

- | | |
|---|---------------|
| 1) Toronto Western Spasmodic Torticollis Scale (TWSTS) | July 31, 2006 |
| 2) Jankovic Rating Scale (JRS) in Blepharospasm | Nov. 28, 2006 |
| 3) Unified Parkinson's Disease Rating Scales (UPDRS) | 2006-Current |
| 4) Botox Injection Training with Cervical Dystonia patients | Aug. 20, 2008 |
| 5) Columbia-Suicide Severity Rating Scale (C-SSRS) | Mar. 04, 2011 |

Civic Organizations:

- | | |
|--|-----------|
| Rotary International, Torrey Pines Chapter | |
| Active Member | 1973-1993 |
| Senior Active | 1993-1994 |
| Paul Harris Fellow | 1986 |

Elected Medical Memberships:

- | | |
|--|-----------|
| 1) Alternate delegate to the California Medical Association | 1978-1981 |
| 2) Delegate to California Medical Association | 1981-1984 |
| 3) Chairman, Medical Services Committee for San Diego County Medical Society | 1975-1977 |
| 4) Board of Directors, San Diego County Medical Society PSRO | 1978 |
| 5) Scripps Memorial Hospital Executive Medical Committee, Member at Large | 1978-1981 |
| 6) Scripps Memorial Hospital Supervisory Committee, Encinitas | 1978-1982 |
| | 1985-1987 |
| 7) Scripps Memorial Hospital Medical Supervisory Committee, La Jolla | 1988-1990 |
| 8) Scripps Memorial Hospital La Jolla | 1998-1990 |
| Chairman, Section of Neurology | 2003-2005 |
| 9) Scripps Memorial Hospital La Jolla | 1982-1983 |
| Chairman, Section of Neurophysiology, (EEG, ENG, EMG, Evoked Potentials and Audiology) | 1987-1990 |
| 10) Scripps Memorial Hospital Encinitas, Chairman, Section of Neurology | 1985-1987 |

Appointed Positions:

- | | |
|---|-----------|
| 1) Scripps Memorial Hospital La Jolla, McDonald Supervisory Committee | 1979-1985 |
| 2) Scripps Memorial Hospital International Committee | 1989-1991 |
| 3) Scripps Memorial Hospital La Jolla, Physicians Health and Well Being Committee | 1985-2008 |
| 4) Chairman, Physician's Health and Well Being Committee (current) | 1993-1996 |
| | 1998-2008 |
| 5) Project Scripps Neuro/Rehab/Orthopedic Clinical Work Group for Scripps Health | 1997-1998 |
| 6) Editorial Board, San Diego County Physician Magazine | 1985-1986 |

Appointed/Elected Positions for Foundation:

- | | |
|--|-----------|
| 1) Ellen Browning Scripps Society, Board Member | 1986-1994 |
| | 1996-2001 |
| 2) Ellen Browning Scripps Society, Chairman | 1990-1993 |
| 3) Friends of Scripps Board | 1993-2005 |
| 4) Scripps Memorial Hospital Foundation Board | 1991-1993 |
| 5) Scripps Memorial Hospital Foundation, Board of Directors, Vice Chairman of Development | 1992-1993 |
| 6) Scripps Memorial Hospital Development Committee | 1992-1993 |
| 7) Scripps Institute of Medicine & Science (SIMS) Foundation Board | 1993-2000 |
| 8) Scripps Institute of Medicine & Science (SIMS) Foundation Executive Cabinet | 1994-1998 |
| 9) Scripps Institute of Medicine & Science (SIMS) | 1993-1996 |
| Foundation Development & Funding Priorities Committee | |
| 10) Fund for Greatness, Executive Cabinet | 1988-1993 |
| 11) Ellen Browning Scripps Society Medalist, Award Nominating Committee Chairman | 1987-2006 |
| 12) Arts and Advisory and Acquisition Committee, Scripps Memorial Hospital La Jolla | 1992-1993 |
| 13) Scripps Rehabilitation Community Advisory Committee, Scripps Memorial Hospital Encinitas | 1993-1997 |
| 14) Community Advisory Board, Scripps Memorial Hospital La Jolla | 1995-2001 |

15) Continuing Medical Education Committee 2005-2006

Other Elected Positions:

- 1) Hospital Staff Medical Group, Board Member 1979-1986
 - 2) Hospital Staff Medical Group, Treasurer 1984-1986
 - 3) XIMED Board Member 1986-1994
 - 4) XIMED Treasurer 1986-1993
 - 5) San Diego Neurological Society President 1985-1986
 - 6) San Diego Neurological Society Secretary 1983-1984
 - 7) San Diego Neurological Society Program Chairman 1981-1982
- 1973-1975

Advisor of Medical Organization:

- San Diego Parkinson's Disease Information Center (APDA)
Medical Director (current) 1986-2008
Board Member 1986-2010

Honors:

- 1) Purple Key Society, Iowa State Teacher's College (Now University of northern Iowa) Cedar Falls, Iowa 1961
- 2) CHAD Civic Volunteer of the Year Award 1991
- 3) Pacific Region, NAIFEH and Smith 1996-2001
- 4) "Who's Who in Medicine and Healthcare" 1998-2009
- 5) "Top Doctors in America" 2002
- 6) "The Best Doctors in America" 2002-2010
- 7) Healthcare Champions Award, San Diego Business Journal 2008
- 8) Kipling's Who's Who Aug. 2009
- 9) "Guide to America's Top Physicians" 2009 Edition, Consumers' Research Council of America 2009

Publications/Articles/Bibliography:

- 1) "Amantadine HCL and Parkinson's Disease" 1971
Silver, D.E., Sahs, A.L., Trans of Ana (book) P.307-308
- 2) "Livedo Reticularis in PD Patients Treated with Amantadine HCL" July 1972
Silver, D.E., Sahs, A.L., Neurology, P.665-669
- 3) "Amantadine HCL, Parkinson's Disease and Dopa Metabolites" July 1972
Silver, D.E., Routh, F., Sahs, A.L. Anderson, R.
Bulletin of Los Angeles Neurological Society, Vol. 37, P.148
- 4) "Amantadine HCL, Parkinson's Disease and Catecholamines" June 1975
Silver, D.E., Routh, F., Sahs, A.L., Iowa Medical Journal
- 5) "Treatment of Parkinson's Disease With Amantadine HCL" 1972
Silver, D.E., Sahs, A.L., Parkinson's Disease and Symmetrel-DuPont
- 6) "Tonic Seizures in Multiple Sclerosis" 1972
Silver, D.E., Electroencephalography Clin. Neurophysical
- 7) "Amantadine in Parkinson's Disease" July 1975
Butzer, J.F., Silver, D.E., Sahs, A.L., Neurology 25 P.603-606
- 8) "Epsilon Aminocaproic Acid for SAH" Feb. 1980
Silver, D.E., Western Journal of Medicine P.1.43
- 9) Emergency Medicine Symposium I, Text, Chapter I-"Headaches" 1979
Post-Graduate Institute for Emergency and Primary Care Physicians, Text Revised 1984, 1988, 1992
- 10) "Seizures and Status Epilepticus" Chapter 1979
Text revised 1984, 1988, and 1992
- 11) "Infectious Diseases of the Nervous System" Chapter 1979
- 12) "Early Diagnosis of Parkinson's Disease" Parkinson's Post, Vol. 10, #2
APDA Publication from Parkinson's Disease Information Referral Center
- 13) "Algorithm For The Treatment of Parkinson's Disease" Supplement Dec. 1994
Koller, W., Silver, D.E., Lieberman, A.,
The American Academy of Neurology, Vol. 44, No.12, supplement 10
- 14) Consensus, "Treatment of Parkinson's Disease" Neurology News 1994

Publications/Articles/Bibliography, cont...

- 15) Consensus, "Treatment of Parkinson's Disease" Geriatric News 1994
- 16) "The Use of Clozapine In The Treatment of Psychosis in Parkinson's Patients" 1995
Silver, D.E., Parkinson's Post, Vol. 12
- 17) "Rational Treatment of Parkinson's Disease With Combination Therapy" 1995
Parkinson's Post, Vol. 14
- 18) "Treatment of Parkinson's Disease With Video Accompaniment" 1995
- 19) "The Use of Clozaril In The Treatment of Psychosis In Parkinson's Disease" 1995
APDA Parkinson's Post, Winter Edition, New Jersey
- 20) "Practical Considerations In Management of Parkinson's Disease" Procedures of a Round 1995
Table Discussion, Educational Service by Sandoz Pharmaceutical Company and Summerset
- 21) "Overview Of A Algorithm For The Management of Parkinson's Disease" June 1995
An update on long-term care drug therapy, a service of NARD
- 22) "Surgical Management of Parkinson's Disease And Experimental Procedure" 1995
Silver, D.E., Parkinson's Post Vol. 12 No.3
- 23) "New Drug Therapy For The Treatment of Parkinson's Disease" 1996
Parkinson's Post Vol.13 No.2
- 24) "COMT Inhibitors And Sinemet CR, Parkinson's Post Vol. 14 No.1 1997
- 25) "Chronic Deep Brain Stimulation in Parkinson's Disease" 1997
Parkinson's Post Vol. 14 No.1
- 26) "The Initiation of Therapy in Parkinson's Disease" Chapter Supplement July 1998
American Academy of Neurology
- 27) "Algorithm For The Treatment of Parkinson's Disease" Koller, et al., chapter supplement 1997
- 28) "The Use of COMT Inhibitors, Talcapone (Tasmar) in The Treatment of Parkinson's Disease" 1998
San Diego Post, Vol. 15 No.2
- 29) "Alternative, Complementary, Integrative Medicine in Parkinson's" 1998
Parkinson's Post, Vol. 15 No.4
- 30) "A Glossary For Parkinson's Patients" Parkinson's Post Vol. 16 No.2 1998
- 30) "Essential Tremor" Parkinson's Post, Vol. 17 No.3 2000
- 31) "Becket, Waiting for Godot, Theatre of the Absurd and the Scripps Health Board" May 31, 2000
San Diego Union-Tribune, Letter to the Editor
- 32) "Perspectives on CNS Disease Management" Neura Vol. #2, BioScience Communications Spring 2002
P. K. Coyle, M.D., C. C. Ford, PhD., K. P. Johnson, M.D., F. D. Lublin, M.D., H. Panitch, M.D.,
D. E. Silver, M.D., and J. S. Wolinsky, M.D.
- 33) Global Parkinson's Disease Study Report: Publication 2002
- 34) "Sleep Disorders in Parkinson's Disease (IPD)" Parkinson's Post, Spring 2002
- 35) "Dopamine Agonists: Potential to Slow the Progression of Parkinson's Disease" 2002
Parkinson's Post, Summer
- 36) "New Anti-Parkinson's Medicines on the Horizon-Apomorphine" Parkinson's Post, Fall 2002
- 37) "Ask the Doctor..." Deep Brain Stimulation (DBS), Parkinson's Post, Winter 2002
- 38) "Soon Available to Help, Stalevo, A New Combination Medication" Parkinson's Post, Fall 2003
- 39) "Apomorphine" Parkinson's Post, Winter 2003
- 40) "Motor Fluctuations in Parkinson Patients" Parkinson's Post, Winter 2003
- 41) "Perspectives on CNS Disease Management" Neura Vol. #3, BioScience Communications Spring 2003
P. K. Coyle, M.D., C. C. Ford, PhD., K. P. Johnson, M.D., F. D. Lublin, M.D., H. Panitch, M.D.,
D. E. Silver, M.D., and J. S. Wolinsky, M.D.
- 42) "Perspectives on CNS Disease Management" Neura Vol. #4, BioScience Communications April 2003
P. K. Coyle, M.D., C. C. Ford, PhD., K. P. Johnson, M.D., F. D. Lublin, M.D., H. Panitch, M.D.,
D. E. Silver, M.D., and J. S. Wolinsky, M.D.
- 43) "Apomorphine" The American Parkinson Disease Association Newsletter, Winter 2003-2004
- 44) "Rotigotine, A Dopamine Agonist for the Treatment of Early Parkinson's Disease" 2004
Parkinson's Post, Spring
- 45) "Rotigotine, A dopamine Agonist for the Treatment of Early Parkinson's Disease" 2004
Parkinsonian People, Summer
- 46) "Rasagiline, A New MAO Type B Inhibitor for the Treatment of Early Parkinson's Disease" 2004
Parkinson's Post, Summer
- 47) "Restless Leg Syndrome (RLS) and Parkinson's Disease (IPD), Diagnosis and Treatment" 2004
Parkinson's Post, Winter

Publications/Articles/Bibliography, cont...

- 48) "Istradefylline (KW-6002) as Adjunctive Therapy in Patients With Advanced Parkinson's Disease: A Positive Safety Profile With Supporting Efficacy" MDS 8th International Congress, Rome, Italy, Dr. Mark Stacy and 6002-US-005/006 Clinical Investigator Group, Poster June 2004
- 49) "Off" Time Reduction From Adjunctive Use of Istradefylline (KW-6002) in Levodopa-Treated Patients with Advanced Parkinson's Disease, MDS 8th International Congress in Rome, Italy, Dr. Peter A. LeWitt and 6002-US-005/006 Clinical Investigator Group, Poster June 2004
- 50) "Levodopa dose fluctuations and complications" Patient Profiles Series, Dee E. Silver, M.D. Jan. 2005
- 51) "Clinical Aspects of the "Wearing-Off" Phenomenon in Patients with Parkinson's Disease: New Treatment Strategies" Symposium Reporter, R.A. Hauser, S.H. Isaacson, D.E. Silver July 2005
- 52) "Important Recent Advances in Parkinson's Disease: Part 1 of 2" Parkinson's Post Jul/Aug. 2005
- 53) "New Educational Campaign to Support People Living With Parkinson's Disease" FightForMORE.com July 2005
- 54) "Current Management of RLS" Monogram, co-editor, The Consultant 2005
- 55) "Parkinsonism" Conn's Current Therapy, Dee E. Silver 2005 & 2006
- 56) "Implications of Motor Fluctuations in Parkinson's Patients on Chronic Therapy (IMPACT) Registry: Quality of Life Date, World Parkinson Congress, Wilson, R, Silver, D, Spears, JB, Van Lunen, B, Washington, DC, Poster Feb. 3, 2006
- 57) "Impact of Functional Age on the Use of Dopamine Agonists in Patients With Parkinson's Disease" The Neurologist, Vol.12, Number 4 July 2006
- 58) "Early Diagnosis and Combination Therapy Hold Keys to Alzheimer's Treatment" Rancho Santa Fe Review Aug. 10, 2006
- 59) "Restless Leg Syndrome (RLS)", Parkinson's Post Oct. 2006
- 60) "Help for Migraine Pain" North County Paper 2006
- 61) "New Advances in Parkinson's Medication" Parkinson's Post Nov./Dec. 2006
- 62) "MAO-B Inhibitors Used in the Treatment of Parkinson's Disease" Parkinson's Post Jan./Feb. 2007
- 63) "Diet Considerations and Warnings for the New MAO Type B Inhibitors" Parkinson's Post April/May 2007
- 64) "Pharmacological Management of Parkinson's Disease in Long-Term Care Residents" The Director, Vol. 15, Number 2 Spring 2007
- 65) "Apomorphine for the Acute Treatment of "off" Episodes in Parkinson's Disease" Elsevier Journal, Review, Mark Stacy, Dee Silver July 2007
- 66) "Fragile X and Movement Disorders" July 24, 2007
- 67) "Get the Facts on Brain Aneurysm", North County Paper Aug. 2007
- 68) "The Patches Are the New Buzz" Parkinson's Post Oct./Nov. 2007
- 69) "Tremor in Infectious Diseases" Infectious Tremor Chapter, Handbook of Essential Tremor and Other Tremor Disorders, Dee E. Silver, M.D. 2008
- 70) "LEGATO: Early Rapid Clinical Benefit With Azilect (rasagiline tablets) as Mono and Adjunct Therapy on Parkinson's Disease Symptoms" A Multicenter Phase IV Trial, Abstract, Presented at the 60th Annual American Academy of Neurology Meeting in Chicago, Illinois R. Wilson, L. Seeberger, D. Silver, A. Griffith, J. Conner, and P. Salzman, Poster April 12-19, 2008
- 71) "I Saw the Look In His Face- Then it Happened" Parkinson's Post April/May 2008
- 72) "Early, Nondisabling Parkinson's Disease: Weighing the Options for Initial Therapy" Elsevier Journal, Neurologic Clinics, Dee E. Silver, M.D. May 21, 2008
- 73) "Ropinirole 24-hour Prolonged Release (Requip XL) Clinical Trial Results" Parkinson's Post Jul./Aug. 2008
- 74) "The Safety and Efficacy of Istradefylline, an Adenosine A2A Antagonist, as Monotherapy in Parkinson's Disease" Poster #251, Dr. Hubert H. Fernandez for the 6002-US-051 Clinical Investigator Group 2008
- 75) "Long-term Safety and Tolerability of Istradefylline as Adjunctive Therapy to Levodopa in Patients With Parkinson's Disease and Motor Complications" Poster #635 Dr. John M. Bertoni for the 6002-INT-001 Clinical Investigator Group 2008
- 76) "The Addition of Orally Disintegrating Selegiline in Parkinson's Disease Patients Experiencing Dopamine Agonist Related Adverse Events: The A to Z Study" Poster Rajesh Pahwa, M.D., Kelly Lyons, PhD, and the A to Z Study Investigators 2008
- 77) "Tolerability and Efficacy of Switching From Swallowed Selegiline to Zidis Selegiline (Zelapar) in Patients with Parkinson's Disease" William G. Ondo, Christine Hunter, Stuart H. Isaacson, Dee E. Silver, R. Malcom Stewart, James W. Tetrud, Anthony Davidson 2008
- 78) "Mirapex Virtual Bibliography Transcript" Movement Disorder Meeting, Chicago, Illinois Sep. 2008

Publications/Articles/Bibliography, cont...

- 79) "A 12-Week, Placebo-Controlled Study (6002-US-006) of Istradefylline in Parkinson's Disease" M. Stacey, D. Silver, T. Mendis, J. Sutton, A. Mori, P. Chaikin, N.M. Sussman Recent Abstracts from "Neurology" issue 71 Oct. 7, 2008
- 80) "North American Subgroup Analysis of the FIRST-STEP Trial of Levodopa/carbidopa/ entacapone and Levodopa/carbidopa in Patients With Early Parkinson's Disease" R.A. Hauser, MD, D.E. Silver, MD Oct. 2008
- 81) "Open-Label Effectiveness of Oral Rasagiline Taken Once-daily (LEGATO) and Determination of Time to Onset of Antiparkinsonian Effect in Monotherapy and Adjunct Therapy Idiopathic Parkinson's Disease" Ronald E. Wilson, Lauren C. Seeberger, Dee E. Silver, Alida Griffith, Jill B. Conner, Phyllis M. Salzman, on behalf of the LEGATO investigators, Manuscript Nov. 2008
- 82) "Study of Istradefylline in Patients With Parkinson's Disease on Levodopa With Motor Fluctuations" co-author with members of the 6002-US-013 group, "Movement Disorders" Nov. 2008
- 83) "Orally Disintegrating Selegiline in Parkinson's Patients With Dopamine Agonist Related Adverse Effects" Kelly E. Lyons, PhD, Joseph H. Friedman, MD, Neal Hermanowitz, MD, Stuart H. Isaacson, MD, Robert A. Hauser, MD, Bonnie P. Hersh, MD, Dee E. Silver, MD, James W. Tetrud, MD, Lawrence W. Elmer, MD, Sotirios Parashos, MD, Lynn K. Struck, MD, Mark F. Lew, MD, Rajesh Pahwa, MD, Manuscript Dec. 2008
- 84) "Intermittent Subcutaneous Apomorphine Therapy for Off Episodes in Parkinson's Disease: A Six Month Open-Label Study" Richard M. Trosch, MD, Dee Silver, MD, Peter B. Bottini, PhD Parkinsonism and Other Related Disorders, Volume 15, Issue SUPPL. 4, Year 2010 Feb. 2009
- 85) "Five Important Advances in Parkinson's Disease in the Last Year" Parkinson's Post Feb./Mar. 2009
- 86) A to Z Manuscript, Clinical Neuropharmacology, Robert Hauser, MD, Joseph Friedman, MD Stuart Isaacson, MD, Bonnie Hersh, MD, Dee Silver, MD, James Tetrud, MD, Lawrence Elmer, MD, Lynn Struck, MD, Mark Lew, MD July 2009
- 87) "Healing Stories-Claire's Story" Scripps Memorial Hospital Website, Dee Silver, MD and Frederick de la Vega, MD August 2009
- 88) "Rasagiline Benefits and Improvement With Rigidity and Akinesia" Article, Dee E. Silver Pending
- 89) "Estimating the Minimal Clinically Importance Difference for the UPDRS Bradykinesia Subscale" Dee E. Silver, Phillip O. Buck, Jane Castelli-Haley, Jill B. Conner 2010
- 90) "Ask The Doctor" Teva Neuroscience Life in Balance Newsletter, Volume 2, Issue 3 Jan. 2011
- 91) "Determining the Efficacy of Rasagiline in Reducing Bradykinesia Among Parkinson's Disease Patients: A Review" Dee E. Silver and Phillip O. Buck, International Journal of Neuroscience, Informa Healthcare 2011
- 92) "The Efficacy of Rasagiline in Reducing Symptoms of Bradykinesia Among Parkinson's Disease Patients: A Review" Dee E. Silver and Phillip O. Buck, AAN Poster Presentation May 2011
- 93) "The Efficacy of Rasagiline in Reducing Symptoms of Bradykinesia Among Parkinson's Disease Patients: A Review" Dee E. Silver and Phillip O. Buck, AAN Poster Presentation June 2011

Formal Presentations:

- 1) Amantadine HCL Treatment in Parkinson's Disease, Parkinson's Conference Wilmington, Delaware Aug. 1970
- 2) Amantadine and Dopa Metabolites, Western Foundation of Neuro Services Newport Beach, California Feb. 1972
- 3) Tonic Seizures in Multiple Sclerosis, Western EEG Society, San Diego, California Feb. 1973
- 4) Ellen Browning Scripps Society Medal, San Diego, California Nov. 12, 2001
- 5) Ellen Browning Scripps Society Medal, Presenter, San Diego, California Nov. 5, 2002
- 6) Ellen Browning Scripps Society Medal, Presenter, San Diego, California Nov. 10, 2003
- 7) Spirit of Life Award Dinner, Rancho Santa Fe, California Oct. 3, 2004
- 8) Ellen Browning Scripps Society Medal, Presenter, San Diego, California Nov. 15, 2004
- 9) Cooking Up Strategies for Movement Disorders and Epilepsy, CME Café, GSK 2006
- 10) KPBS Radio, Maureen Cavanaugh Show, Diagnosing Idiopathic Parkinson's Disease July 27, 2009
- 11) WealthTV, Parkinson's Disease Interview Sep. 15, 2009

Clinical Research Investigator:

1) Felbatol in Epilepsy, Landmark Investigation	1993-1994
2) IND for Cognex	1992-1994
3) Imitrex Injection, Post marketing surveillance study	1994
4) Neurontin, Dose Titration Study	1994
5) TPA in the Treatment in Strokes, sub-investigator Published in the New England Journal of Medicine	Dec. 1995
6) Ancrod and the Treatment of Strokes, sub-investigator	
7) Cerestat in the Treatment of Strokes, sub-investigator	
8) Exelon in the Treatment of Alzheimer's Disease	
9) Tasmar in the treatment of fluctuating Parkinson's Disease patients	
10) Entacapone in the Treatment of non-fluctuating Parkinson's Disease patients	
11) Zydys in the Treatment of Parkinson's Disease	
12) Roludex in the Treatment of Parkinson's Disease	
13) Entacapone, Treatment of post four hour fluctuators in Parkinson's Disease	
14) Apomorphine in the treatment of Parkinson's Disease	2000-2005
15) Permax, Use as monotherapy in Parkinson's Disease	
16) Maxalt, Use in Migraine failed patients	
17) Apomorphine, Use in Parkinson's, 3 month study with Pharmacological Study	
18) Apomorphine, Orthostatic Hypotension Study	
19) Myotrophin Injection, for patients with Amyotrophic Lateral Sclerosis	1996
20) Rebif, Phase III, in patients with Relapsing Remitting Multiple Sclerosis	2001-2003
21) Pfizer/Sumanriole, Phase III, double-blind, in patients with Early Parkinson's disease	2001-2003
22) Pfizer/Sumanriole, Phase III, open-label, in patients with Early Parkinson's disease	2001-2004
23) Pfizer/Sumanriole, Phase III, double-blind, in patients with Parkinson's disease	2001-2004
24) Kyowa/KW6002 (006), Phase III, double-blind, in patients with Parkinson's, Top Enrollers	2002-2004
25) Kyowa/KW6002 (007), Phase III, open-label, in patients with Parkinson's, Top Enrollers	2002-2004
26) Novartis/Stalevo, in patients diagnosed with Parkinson's disease, High Enrollers	2002-2004
27) Teva/Copaxone "READY" Trial, in patients with Relapsing Remitting MS	2003-2004
28) Berlex/Betaseron "ABOVE" Trial, in patients with Relapsing Remitting MS	2003-2004
29) Berlex/Betaseron "BEYOND" Trial, in patients with Relapsing Remitting MS	2004-2007
30) Teva/Copaxone "ACHIEVE" Trial, in patients with Relapsing Remitting MS	2004-2005
31) Sarizotan "PADDY-1" Trial, in patients with Parkinson's disease and disabling dyskinesias	2004-2006
32) Stalevo "STRIDE" Trial, in newly diagnosed Parkinson's disease, High Enrollers	2004-2008
33) Kyowa/Istradefylline/KW6002 (013) Phase III Trial, in patients with Parkinson's disease	2004-2006
34) Kyowa/Istradefylline/KW6002 (001) Phase III Trial, in patients with Parkinson's disease	2004-2006
35) Novartis/Stalevo "QUEST" Phase III Trial, in patients with Parkinson's disease and Experiencing "Off" time	2005-2008
36) Novartis/Stalevo "FIRST STEP" Phase III Trial, in newly diagnosed Parkinson's disease Patients, High Enrollers	2005-2008
37) Sarizotan "PADDY-O" Phase III Trial, open-label, in patients with Parkinson's disease	2005-2006
38) Kyowa/Istradefylline/KW6002 (025), safety study in patients with Parkinson's disease	2005-2008
39) Teva/Azilect "LEGATO" Phase III Trial, in patients with Parkinson's disease, Top Enroller	2006-2007
40) Eisai/E2007 "PACE" Phase III Trial, in patients with Parkinson's disease	2006-2008
41) Merz/NT201 Phase III Trial, in patients with Cervical Dystonia	2006-2008
42) Teva "NAb's Phase IV Trial, NAb's testing in patients diagnosed with Multiple Sclerosis	2006-2008
43) Eisai/E2007 "PACE-FU" Phase III Trial, in patients with Parkinson's disease	2007-2008
44) Merz/NT201 Phase III Trial, in patients with Bilateral Blepharospasm	2007-2009
45) Solvay/SLV308 "MONDRIAN" Phase III Trial, in patients with Parkinson's disease	2007-2008
46) Valeant/Zelapar "A to Z" Phase IV Trial, in patients with Parkinson's disease	2007-2008
47) Valeant/Zelapar "SWITCH" Phase IV Trial, in patients with Parkinson's disease	2007-2008
48) Vernalis/Tigan "APO-01" Trial in patients with Parkinson's initiating Apokyn, Top Enrollers	2007-2008
49) Boehringer Ingelheim/Pramipexole ER "PROUD" Phase III Trial, in newly diagnosed Parkinson's disease patients	2007-2009
50) Santhera/Fipamezole "FJORD" Phase III Trial, in patients with Parkinson's disease	2007-2008
51) Schwarz/Rotigotine (Neupro) "SP921" Phase IV Trial, in patients diagnosed with Parkinson's Disease	2007-2011

Clinical Research Investigator, cont...

52)	Boehringer Ingelheim/Pramipexole ER "524" Phase III Trial, in newly diagnosed Parkinson's Disease patients	2007-2008
53)	Boehringer Ingelheim/Pramipexole ER "633" Phase III, Open-label Trial, in newly diagnosed Parkinson's disease patients	2007-2010
54)	Schering-Plough/SCH420814 "P04501" Phase II, Double-blind Trial, in late stage Parkinson's Disease patients	2007-2008
55)	Schering-Plough/SCH420814 "P05175" Phase II, Open-label Trial, in late stage Parkinson's Disease patients	2008-2010
56)	Teva/Glatiramer Acetate, double-blind, in Retinal Nerve Fiber Layer and Visual Function in Patients with a First Episode of Acute Optic Neuritis	2008-2009
57)	Teva/Glatiramer Acetate "SONG" Phase IV Trial, in patients with Multiple Sclerosis	2008-2009
58)	Novartis/Stalevo, double-blind Trial, in patients with Parkinson's Disease and demonstrating Non-motor Symptoms of wearing off	2008-2009
59)	Novartis/Exelon Patch and Capsules "OPTIMA" Open-label Trial, in patients with Parkinson's Disease with mild to moderately severe dementia	2007-2009
60)	Impax/IPX066 "APEX-PD" Phase III, Placebo-controlled Trial, in patients with mild Parkinson's disease	2009-2011
61)	Impax/IPX066 "ADVANCE-PD" Phase III Trial, in patients with advanced Parkinson's disease	2009-2011
62)	Teva/Azilect "ANDANTE" Phase IV Trial, in patients with early Parkinson's disease	2009-ongoing
63)	Impax/IPX066 "Open Label Extension" Phase III Trial, in patients with Parkinson's disease	2010-2011
64)	Novartis "AFQ2216" Phase II Trial, in patients with advanced Parkinson's disease	2010-2011
65)	Ipsen "Tigan" Phase III Trial, in Parkinson's disease patients ready to begin Apokyn	2010-2011
66)	Teva "ENCORE" Phase III Trial, in MS patients, with 3xweek dosing of Copaxone	2010-2011
67)	Acadia "ACP-103-020" Phase III Trial, in patients with Parkinson's disease psychosis	2010-ongoing
68)	Teva "GALA" Phase III Trial, in newly diagnosed Multiple Sclerosis patients	2010-ongoing
69)	Phytopharm/Cogane "CONFIDENT-PD" Phase II Trial, in newly diagnosed Parkinson's Disease patients	2010-ongoing
70)	Biotie (formally Synosia)/SYN115 "SYN115-CL02" Phase II Trial, in Parkinson's Disease Patients with end-of-dose wearing off	2011-ongoing
71)	Addex/ADX48621, Phase II Trial, in LDopa induced dyskinesia in patients with Parkinson's Disease	2011-ongoing
72)	Merz "XCiDaBLE" Phase IV Observational Trial, evaluation of Xeomin for Cervical Dystonia or Blepharospasm	2011-ongoing
73)	Avanir "PRISM" Registry: A Pseudobulbar Affect Registry Series	2011-ongoing
74)	Biogen "STRATIFY-2" Trial, JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri	2011-ongoing
75)	Ipsen "ANCHOR-CD" Phase IV Observational Trial, Dysport clinical and health economics outcomes registry in Cervical Dystonia	2011-ongoing

Global Parkinson's Disease Study By World Health Organization: One of the centers selected for evaluation of treatment of IPD.

ICH/GCP Certification and Training:

1)	Collaborative IRB Training Initiative (CITI) Program, Protection of Human Research Subjects	Dec. 14, 2007
2)	Good Clinical Practice (GCP) E-learning Training, Novartis Pharmaceuticals	April 13, 2009
3)	Protecting Human Research Participants, National Institutes of Health Web-based Training	Mar. 18, 2010

Invitation for Panel Participation:

1)	Clinical Studies In Parkinson's Disease, Dupont, Wilmington, Delaware	Feb. 1970
2)	Study of Metabolites of Amantadine HCL in Parkinson's Patients and Dopamine Levels in CSF of Amantadine HCL Treated Patients, Dupont, Wilmington, Delaware	Feb. 1972
3)	Resource Development, Scripps Memorial Hospital Foundation Panel Scripps Memorial Hospital La Jolla	May 1991
4)	Current Treatment Strategies For Parkinson's Disease, Keystone, Colorado	Feb. 1993
5)	Update on Current Treatment Strategies For Parkinson's Disease Board for Treatment of Alzheimer's Disease with Cognex, Keystone, Colorado	Feb. 1994
6)	Advisory, Parke-Davis	April 5, 1994

Invitation for Panel Participation, cont...

7)	Investigators for Cognex Access Program for the treatment of Alzheimer's Disease Dallas Texas	Nov. 5-7, 1993
8)	APDA Conference on Parkinson's Disease Panel	Aug. 19-23, 1992
9)	Consensus Panel on the Treatment of Parkinson's Disease, New York, New York	Jan. 13-14, 1995
10)	Consensus Panel Algorithmic Treatment of Parkinson's Disease With Video Keystone, Colorado	April 5-9, 1995
11)	Scripps Institute of Science and Medicine (SIMS), Independent Teaching Hospitals Development Foundation Conference, Fund Raising Its Relationship to Managed Care	Feb. 24, 1995
12)	Use of Trophic Factors in Neurodegenerative Diseases National Parkinson's Foundation, San Diego, California	Nov. 9, 1995
13)	Second Annual Parkinson's Disease Symposium Satellite Conference, Keystone, Colorado	Mar. 8, 1996
14)	Challenge and Issues, Round Table Meeting, Sheraton Grand Hotel, Tampa, Florida	Feb. 7, 1997
15)	Current Trends in the Treatment of Parkinson's Disease, Revision of the Algorithm for the Treatment of Parkinson's Disease, Heaver Castle, England	Mar. 21-22, 1997
16)	Current Trends in the Treatment of Parkinson's Disease, Napa Valley, California	Feb. 1998
17)	Current Trends in the Use of Eldepryl, New York, New York	Mar. 15, 1998
18)	BOTOX Injection Training with Cervical Dystonia, Allergan Inc.	Sept. 2008
19)	Parkinson's Disease Roundtable, Teva Neuroscience, Dallas, Texas	June 26-27, 2009
20)	Mirapex ER Speakers Council Meeting, Boehringer Ingelheim, Chicago, Illinois	Aug. 13-14, 2009
21)	Mirapex ER Speaker Council Web Cast, San Diego, California	Mar. 3, 2010
22)	Questcor Regional Advisory Board Meeting, Phoenix, Arizona	Mar. 5-6, 2010
23)	Teva Neuroscience, Multiple Sclerosis Regional Advisory Forum, San Diego, California	Mar. 12-13, 2010
24)	Teva Neuroscience, Azilect Case Development Meeting, San Diego, California	July 9-10, 2010
25)	Teva Neuroscience, Multiple Sclerosis Local Advisory Board Meeting, Pasadena, California	Aug. 14, 2010
26)	Teva Neuroscience, 2011 Copaxone Speaker Training Meeting, Plano Texas	Sep. 24-25, 2010
27)	Ipsen Pharmaceuticals, Dysport Regional Advisory Board Meeting, Phoenix, Arizona	Oct. 1-2, 2010
28)	Novartis Pharmaceuticals, Exelon Patch Webcast Speaker Training Series	Oct. 2010
29)	Teva Neuroscience, Azilect Speaker Bureau training Meeting, Scottsdale, Arizona	Oct. 8-9, 2010
30)	Teva Neuroscience, Multiple Sclerosis Local Advisory Meeting, Irvine, California	Nov. 6, 2010
31)	Teva Neuroscience, Regional Multiple Sclerosis Experts' Forum, San Francisco, California	Mar. 18-19, 2011
32)	Teva Neuroscience, Multiple Sclerosis Local Advisory Board Meeting, Pasadena, California	Mar. 26, 2011
33)	Merz Pharmaceutical, Speaker Network Series, San Diego, California	Mar. 29, 2011
34)	Merz Pharmaceutical, Xeomin Advisor, Strategic Roundtable, MDS Annual Meeting, Toronto Canada	June 7, 2011
35)	Ipsen Pharmaceuticals, Dysport Regional Advisory Board Meeting, Phoenix, Arizona	June 17-18, 2011
36)	Teva Neuroscience, Parkinson's Disease Advisory Forum, Chicago, Illinois	Aug. 5-6, 2011
37)	Teva Neuroscience, Multiple Sclerosis National Speaker Bureau Meeting, Frisco, Texas	Sep. 23-24, 2011
38)	Teva Neuroscience, Azilect Speakers Bureau Webcast Program	Nov. 02, 2011
39)	Teva Neuroscience, Multiple Sclerosis Local Advisory Meeting, Irvine, California	Nov. 12, 2011

Advisory Boards, Consensus Meetings, Speaker Meetings, Investigator's Meetings:

Code: PD =Parkinson's Disease, HA=Headache, DAT=Dementia Alzheimer's Type,
SX=Seizure Disorder, MS =Multiple Sclerosis, HD=Huntington's Disease

1985:	PD-2				
1986:	PD-3	HA-1	SX-1		
1987:	PD-4	HA-1			
1988:	PD-4			SX-1	
1989:	PD-4				Botox-1
1990:	PD-4	HA-1	DAT-2	SX-2	Botox-1
1991:	PD-5	HA-2	DAT-2	SX-1	Botox-1
1992:	PD-4	HA-2	DAT-3	SX-1	Botox-1
1993:	PD-4	HA-1	DAT-2	SX-1	Botox-1 Stroke-2
1994:	PD-3	HA-2	DAT-2		Botox-1 Stroke-1
1995:	PD-5	HA-1	DAT-3	MS-2	Botox-1 Stroke-1
1996:	PD-3	HA-1	DAT-3	MS-2	Stroke-2
1997:	PD-4	HA-2	DAT-4	MS-3	Stroke-2

1998:	PD-4	HA-2	DAT-3	MS-3		Stroke-1	
1999:	PD-5	HA-3	DAT-4	MS-3		Stroke-2	
2000:	PD-4	HA-4	DAT-4	MS-4	Botox-1	Stroke-2	
2001:	PD-4	HA-1	DAT-3	MS-2	Botox-1	SX-1	
2002:	PD-6	HA-2	DAT-4	MS-4	Botox-1		
2003:	PD-5	HA-2	DAT-4	MS-3	Botox-1		
2004:	PD-7	HA-1	DAT-5	MS-4	Botox-1		
2005:	PD-6	HA-2	DAT-6	MS-5	Botox-2		
2006:	PD-8	HA-1	DAT-4	MS-5	Botox-1		
2007:	PD-8	HA-1	DAT-4	MS-6	Botox-2		
2008:	PD-10	HA-1	DAT-3	MS-5	Botox-1		
2009:	PD-11	HA-1	DAT-2				
2010:	PD-7	HA	DAT-4	MS-4	Botox-2	Dysport-1	
2011:	PD-9	HA-1	DAT-2	MS-6	Botox-1	Dysport-2	Xeomin-2

Neurodegenerative Meetings- Director, Dr. Warren Olanow, Kewstone, Iowa
 Movement Disorder Society (MDS) Meetings, yearly
 American Academy of Neurology (AAN) Meetings, yearly

1987-2004
 1988-present
 1988-present

Revised: January 2012